The Role of Coronary Microvascular Disease in Cardiomyophaties

Main Article Content

Jeremías Bayón Eva-Fernanda Rodriguez-González Melisa Santás-Álvarez Rosa-Alba Abellás-Sequeiros Raymundo Ocaranza-Sánchez Carlos González_Juanatey


Coronary microvascular disease (CMD) makes reference to the anatomically and functionally disorders affecting vascular compartments (<400 mm diameter), covering a broad range of clinical conditions in which the structure and function of the coronary microcirculation is affected. CMD is characterized by an impaired coronary flow reserve (cut-off values of 2.0-2.5) or an abnormally index of coronary microvascular resistance (IMR >25) and/or focal or diffuse vasoconstriction during acetylcholine challenge, with an important role in myocardial perfusion. The aim of this work is to review CMD, definition, clinical manifestations, diagnosis method (non invasive and invasive approach) and the role of CMD in the main cardiomiophaties, such as Hypertrophic cardiomiopathy, none idiomatic dilated cardiomiopathy and infiltrative miocardiophaty.

Article Details

How to Cite
BAYÓN, Jeremías et al. The Role of Coronary Microvascular Disease in Cardiomyophaties. Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022. ISSN 2375-1924. Available at: <>. Date accessed: 19 june 2024. doi:
Research Articles


1. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007;356(8):830-840. doi:10.1056/NEJMra061889
2. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477. doi:10.1093/eurheartj/ehz425
3. Padro T, Manfrini O, Bugiardini R, et al. ESC Working Group on Coronary Pathophysiology and Microcirculation position paper on “coronary microvascular dysfunction in cardiovascular disease.” Cardiovasc Res. 2020;116(4):741-755. doi:10.1093/cvr/cvaa003
4. Shaw LJ, Shaw RE, Merz CNB, et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation. 2008;117(14):1787-1801. doi:10.1161/CIRCULATIONAHA.107.726562
5. Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review. J Am Coll Cardiol. 2018;72(21):2625-2641. doi:10.1016/j.jacc.2018.09.042
6. Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018;250:16-20. doi:10.1016/j.ijcard.2017.08.068
7. Amann K, Wiest G, Zimmer G, Gretz N, Ritz E, Mall G. Reduced capillary density in the myocardium of uremic rats--a stereological study. Kidney Int. 1992;42(5):1079-1085. doi:10.1038/ki.1992.390
8. Asghar O, Al-Sunni A, Khavandi K, et al. Diabetic cardiomyopathy. Clin Sci Lond Engl 1979. 2009;116(10):741-760. doi:10.1042/CS20080500
9. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 1993;91(1):29-37. doi:10.1172/JCI116183
10. Marinescu MA, Löffler AI, Ouellette M, Smith L, Kramer CM, Bourque JM. Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging. 2015;8(2):210-220. doi:10.1016/j.jcmg.2014.12.008
11. Shah NR, Charytan DM, Murthy VL, et al. Prognostic Value of Coronary Flow Reserve in Patients with Dialysis-Dependent ESRD. J Am Soc Nephrol JASN. 2016;27(6):1823-1829. doi:10.1681/ASN.2015030301
12. Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circ Res. 2018;122(8):1135-1150. doi:10.1161/CIRCRESAHA.118.311912
13. Reindl M, Reinstadler SJ, Feistritzer HJ, et al. Relation of Low-Density Lipoprotein Cholesterol With Microvascular Injury and Clinical Outcome in Revascularized ST-Elevation Myocardial Infarction. J Am Heart Assoc. 2017;6(10):e006957. doi:10.1161/JAHA.117.006957
14. Koller A. Perspectives: Microvascular endothelial dysfunction and gender. Eur Heart J Suppl J Eur Soc Cardiol. 2014;16(Suppl A):A16-A19. doi:10.1093/eurheartj/sut005
15. Zhang Z, Takarada S, Molloi S. Assessment of coronary microcirculation in a swine animal model. Am J Physiol Heart Circ Physiol. 2011;301(2):H402-408. doi:10.1152/ajpheart.00213.2011
16. Radico F, Cicchitti V, Zimarino M, De Caterina R. Angina pectoris and myocardial ischemia in the absence of obstructive coronary artery disease: practical considerations for diagnostic tests. JACC Cardiovasc Interv. 2014;7(5):453-463. doi:10.1016/j.jcin.2014.01.157
17. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 1995;92(3):320-326. doi:10.1161/01.cir.92.3.320
18. Ong P, Athanasiadis A, Borgulya G, Mahrholdt H, Kaski JC, Sechtem U. High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries. The ACOVA Study (Abnormal COronary VAsomotion in patients with stable angina and unobstructed coronary arteries). J Am Coll Cardiol. 2012;59(7):655-662. doi:10.1016/j.jacc.2011.11.015
19. Hamasaki S, Al Suwaidi J, Higano ST, Miyauchi K, Holmes DR, Lerman A. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J Am Coll Cardiol. 2000;35(6):1654-1660. doi:10.1016/s0735-1097(00)00594-5
20. Choi BJ, Matsuo Y, Aoki T, et al. Coronary endothelial dysfunction is associated with inflammation and vasa vasorum proliferation in patients with early atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34(11):2473-2477. doi:10.1161/ATVBAHA.114.304445
21. Patel MR, Peterson ED, Dai D, et al. Low diagnostic yield of elective coronary angiography. N Engl J Med. 2010;362(10):886-895. doi:10.1056/NEJMoa0907272
22. Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. Circulation. 2015;131(1):19-27. doi:10.1161/CIRCULATIONAHA.114.011939
23. Shah NR, Cheezum MK, Veeranna V, et al. Ranolazine in Symptomatic Diabetic Patients Without Obstructive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. J Am Heart Assoc. 2017;6(5):e005027. doi:10.1161/JAHA.116.005027
24. Shimokawa H. 2014 Williams Harvey Lecture: importance of coronary vasomotion abnormalities-from bench to bedside. Eur Heart J. 2014;35(45):3180-3193. doi:10.1093/eurheartj/ehu427
25. Feher A, Sinusas AJ. Quantitative Assessment of Coronary Microvascular Function: Dynamic Single-Photon Emission Computed Tomography, Positron Emission Tomography, Ultrasound, Computed Tomography, and Magnetic Resonance Imaging. Circ Cardiovasc Imaging. 2017;10(8):e006427. doi:10.1161/CIRCIMAGING.117.006427
26. Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated Noninvasive Physiological Assessment of Coronary Circulatory Function and Impact on Cardiovascular Mortality in Patients With Stable Coronary Artery Disease. Circulation. 2017;136(24):2325-2336. doi:10.1161/CIRCULATIONAHA.117.029992
27. Doyle M, Weinberg N, Pohost GM, et al. Prognostic value of global MR myocardial perfusion imaging in women with suspected myocardial ischemia and no obstructive coronary disease: results from the NHLBI-sponsored WISE (Women’s Ischemia Syndrome Evaluation) study. JACC Cardiovasc Imaging. 2010;3(10):1030-1036. doi:10.1016/j.jcmg.2010.07.008
28. Ferreiro DE, Cianciulli TF, Saccheri MC, et al. Assessment of coronary flow with transthoracic color Doppler echocardiography in patients with hypertrophic cardiomyopathy. Echocardiogr Mt Kisco N. 2013;30(10):1156-1163. doi:10.1111/echo.12242
29. Ong P, Athanasiadis A, Borgulya G, et al. Clinical usefulness, angiographic characteristics, and safety evaluation of intracoronary acetylcholine provocation testing among 921 consecutive white patients with unobstructed coronary arteries. Circulation. 2014;129(17):1723-1730. doi:10.1161/CIRCULATIONAHA.113.004096
30. Modi BN, Rahman H, Sherif SA, et al. Is heart rate response a reliable marker of adenosine-induced coronary hyperemia? Int J Cardiovasc Imaging. 2018;34(7):1117-1125. doi:10.1007/s10554-018-1309-1
31. Pijls NHJ, Fearon WF, Tonino PAL, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study. J Am Coll Cardiol. 2010;56(3):177-184. doi:10.1016/j.jacc.2010.04.012
32. Layland J, Carrick D, McEntegart M, et al. Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2013;6(3):231-236. doi:10.1161/CIRCINTERVENTIONS.112.000180
33. Berry C. Stable Coronary Syndromes: The Case for Consolidating the Nomenclature of Stable Ischemic Heart Disease. Circulation. 2017;136(5):437-439. doi:10.1161/CIRCULATIONAHA.117.028991
34. Pijls NHJ, De Bruyne B, Smith L, et al. Coronary thermodilution to assess flow reserve: validation in humans. Circulation. 2002;105(21):2482-2486. doi:10.1161/01.cir.0000017199.09457.3d
35. Fearon WF, Kobayashi Y. Invasive Assessment of the Coronary Microvasculature: The Index of Microcirculatory Resistance. Circ Cardiovasc Interv. 2017;10(12):e005361. doi:10.1161/CIRCINTERVENTIONS.117.005361
36. Seitz A, McChord J, Bekeredjian R, Sechtem U, Ong P. Definitions and Epidemiology of Coronary Functional Abnormalities. Eur Cardiol. 2021;16:e51. doi:10.15420/ecr.2021.14
37. Sueda S, Miyoshi T, Sasaki Y, Sakaue T, Habara H, Kohno H. Gender differences in sensitivity of acetylcholine and ergonovine to coronary spasm provocation test. Heart Vessels. 2016;31(3):322-329. doi:10.1007/s00380-014-0614-4
38. Widmer RJ, Samuels B, Samady H, et al. The functional assessment of patients with non-obstructive coronary artery disease: expert review from an international microcirculation working group. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2019;14(16):1694-1702. doi:10.4244/EIJ-D-18-00982
39. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J. 1980;44(6):672-673. doi:10.1136/hrt.44.6.672
40. McKenna WJ, Maron BJ, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circ Res. 2017;121(7):722-730. doi:10.1161/CIRCRESAHA.117.309711
41. Dorbala S, Vangala D, Bruyere J, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2(4):358-367. doi:10.1016/j.jchf.2014.03.009
42. Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733-2779. doi:10.1093/eurheartj/ehu284
43. Udelson JE, Bonow RO, O’Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation. 1989;79(5):1052-1060. doi:10.1161/01.cir.79.5.1052
44. Krams R, Ten Cate FJ, Carlier SG, Van Der Steen AFW, Serruys PW. Diastolic coronary vascular reserve: a new index to detect changes in the coronary microcirculation in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43(4):670-677. doi:10.1016/j.jacc.2003.09.046
45. Yang EH, Yeo TC, Higano ST, Nishimura RA, Lerman A. Coronary hemodynamics in patients with symptomatic hypertrophic cardiomyopathy. Am J Cardiol. 2004;94(5):685-687. doi:10.1016/j.amjcard.2004.05.046
46. Sciagrà R, Passeri A, Bucerius J, et al. Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging. 2016;43(8):1530-1545. doi:10.1007/s00259-016-3317-5
47. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol. 1998;31(5):1089-1096. doi:10.1016/s0735-1097(98)00036-9
48. Pries AR, Badimon L, Bugiardini R, et al. Coronary vascular regulation, remodelling, and collateralization: mechanisms and clinical implications on behalf of the working group on coronary pathophysiology and microcirculation. Eur Heart J. 2015;36(45):3134-3146. doi:10.1093/eurheartj/ehv100
49. Camici PG, Olivotto I, Rimoldi OE. The coronary circulation and blood flow in left ventricular hypertrophy. J Mol Cell Cardiol. 2012;52(4):857-864. doi:10.1016/j.yjmcc.2011.08.028
50. Raphael CE, Cooper R, Parker KH, et al. Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy: Insights From Wave Intensity Analysis and Magnetic Resonance. J Am Coll Cardiol. 2016;68(15):1651-1660. doi:10.1016/j.jacc.2016.07.751
51. Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(9):866-875. doi:10.1016/j.jacc.2009.04.072
52. Olivotto I, Cecchi F, Camici PG. Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences. Ital Heart J Off J Ital Fed Cardiol. 2004;5(8):572-580.
53. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996;93(5):841-842. doi:10.1161/01.cir.93.5.841
54. Towbin JA, Bowles NE. The failing heart. Nature. 2002;415(6868):227-233. doi:10.1038/415227a
55. Maron BJ, Towbin JA, Thiene G, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 2006;113(14):1807-1816. doi:10.1161/CIRCULATIONAHA.106.174287
56. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104(4):557-567. doi:10.1016/s0092-8674(01)00242-2
57. Parodi O, De Maria R, Oltrona L, et al. Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation. Circulation. 1993;88(2):509-522. doi:10.1161/01.cir.88.2.509
58. Roura S, Bayes-Genis A. Vascular dysfunction in idiopathic dilated cardiomyopathy. Nat Rev Cardiol. 2009;6(9):590-598. doi:10.1038/nrcardio.2009.130
59. Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. Arch Intern Med. 2006;166(17):1805-1813. doi:10.1001/archinte.166.17.1805
60. Larsen BT, Mereuta OM, Dasari S, et al. Correlation of histomorphological pattern of cardiac amyloid deposition with amyloid type: a histological and proteomic analysis of 108 cases. Histopathology. 2016;68(5):648-656. doi:10.1111/his.12793
61. Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2014;21(4):221-224. doi:10.3109/13506129.2014.964858
62. Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol Off J Soc Cardiovasc Pathol. 2015;24(6):343-350. doi:10.1016/j.carpath.2015.07.008
63. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol. 2016;68(12):1323-1341. doi:10.1016/j.jacc.2016.06.053
64. Neben-Wittich MA, Wittich CM, Mueller PS, Larson DR, Gertz MA, Edwards WD. Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med. 2005;118(11):1287. doi:10.1016/j.amjmed.2005.06.017
65. Desnick RJ, Wasserstein MP. Fabry disease: clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp. 2001;31:317-339.
66. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750-1172-5-30
67. Shah JS, Lee P, Hughes D, et al. The natural history of left ventricular systolic function in Anderson-Fabry disease. Heart Br Card Soc. 2005;91(4):533-534. doi:10.1136/hrt.2004.035584
68. O’Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52(4):326-335. doi:10.1016/j.pcad.2009.11.002
69. Lynch JP, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med. 2014;35(3):372-390. doi:10.1055/s-0034-1376889
70. Vaccarino V, Khan D, Votaw J, et al. Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins. J Am Coll Cardiol. 2011;57(11):1271-1279. doi:10.1016/j.jacc.2010.09.074
71. Kruse MJ, Kovell L, Kasper EK, et al. Myocardial Blood Flow and Inflammatory Cardiac Sarcoidosis. JACC Cardiovasc Imaging. 2017;10(2):157-167. doi:10.1016/j.jcmg.2016.09.023